Background: Neuroblastoma (NB) represents the most frequent and aggressive form of extracranial solid tumor of infants. Although the overall survival of patients with NB has improved in the last years, more than 50% of high-risk patients still undergo a relapse. Thus, in the era of precision/personalized medicine, the need for high-risk NB patient-specific therapies is urgent. Methods: Within the PeRsonalizEd Medicine (PREME) program, patient-derived NB tumors and bone marrow (BM)-infiltrating NB cells, derived from either iliac crests or tumor bone lesions, underwent to histological and to flow cytometry immunophenotyping, respectively. BM samples containing a NB cells infiltration from 1 to 50 percent, underwent to a subsequent NB cells enrichment using immune-magnetic manipulation. Then, NB samples were used for the identification of actionable targets and for the generation of 3D/tumor-spheres and Patient-Derived Xenografts (PDX) and Cell PDX (CPDX) preclinical models. Results: Eighty-four percent of NB-patients showed potentially therapeutically targetable somatic alterations (including point mutations, copy number variations and mRNA over-expression). Sixty-six percent of samples showed alterations, graded as "very high priority", that are validated to be directly targetable by an approved drug or an investigational agent. A molecular targeted therapy was applied for four patients, while a genetic counseling was suggested to two patients having one pathogenic germline variant in known cancer predisposition genes. Out of eleven samples implanted in mice, five gave rise to (C)PDX, all preserved in a local PDX Bio-bank. Interestingly, comparing all molecular alterations and histological and immunophenotypic features among the original patient's tumors and PDX/CPDX up to second generation, a high grade of similarity was observed. Notably, also 3D models conserved immunophenotypic features and molecular alterations of the original tumors. Conclusions: PREME confirms the possibility of identifying targetable genomic alterations in NB, indeed, a molecular targeted therapy was applied to four NB patients. PREME paves the way to the creation of clinically relevant repositories of faithful patient-derived (C)PDX and 3D models, on which testing precision, NB standard-of-care and experimental medicines.

From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models / Capasso, Mario; Brignole, Chiara; Lasorsa, Vito A.; Bensa, Veronica; Cantalupo, Sueva; Sebastiani, Enrico; Quattrone, Alessandro; Ciampi, Eleonora; Avitabile, Marianna; Sementa, Angela R.; Mazzocco, Katia; Cafferata, Barbara; Gaggero, Gabriele; Vellone, Valerio G.; Cilli, Michele; Calarco, Enzo; Giusto, Elena; Perri, Patrizia; Aveic, Sanja; Fruci, Doriana; Tondo, Annalisa; Luksch, Roberto; Mura, Rossella; Rabusin, Marco; De Leonardis, Francesco; Cellini, Monica; Coccia, Paola; Iolascon, Achille; Corrias, Maria V.; Conte, Massimo; Garaventa, Alberto; Amoroso, Loredana; Ponzoni, Mirco; Pastorino, Fabio. - In: JOURNAL OF TRANSLATIONAL MEDICINE. - ISSN 1479-5876. - 22:1(2024). [10.1186/s12967-024-04954-w]

From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models

Capasso, Mario;Lasorsa, Vito A.;Cantalupo, Sueva;Avitabile, Marianna;Mura, Rossella;Iolascon, Achille;
2024

Abstract

Background: Neuroblastoma (NB) represents the most frequent and aggressive form of extracranial solid tumor of infants. Although the overall survival of patients with NB has improved in the last years, more than 50% of high-risk patients still undergo a relapse. Thus, in the era of precision/personalized medicine, the need for high-risk NB patient-specific therapies is urgent. Methods: Within the PeRsonalizEd Medicine (PREME) program, patient-derived NB tumors and bone marrow (BM)-infiltrating NB cells, derived from either iliac crests or tumor bone lesions, underwent to histological and to flow cytometry immunophenotyping, respectively. BM samples containing a NB cells infiltration from 1 to 50 percent, underwent to a subsequent NB cells enrichment using immune-magnetic manipulation. Then, NB samples were used for the identification of actionable targets and for the generation of 3D/tumor-spheres and Patient-Derived Xenografts (PDX) and Cell PDX (CPDX) preclinical models. Results: Eighty-four percent of NB-patients showed potentially therapeutically targetable somatic alterations (including point mutations, copy number variations and mRNA over-expression). Sixty-six percent of samples showed alterations, graded as "very high priority", that are validated to be directly targetable by an approved drug or an investigational agent. A molecular targeted therapy was applied for four patients, while a genetic counseling was suggested to two patients having one pathogenic germline variant in known cancer predisposition genes. Out of eleven samples implanted in mice, five gave rise to (C)PDX, all preserved in a local PDX Bio-bank. Interestingly, comparing all molecular alterations and histological and immunophenotypic features among the original patient's tumors and PDX/CPDX up to second generation, a high grade of similarity was observed. Notably, also 3D models conserved immunophenotypic features and molecular alterations of the original tumors. Conclusions: PREME confirms the possibility of identifying targetable genomic alterations in NB, indeed, a molecular targeted therapy was applied to four NB patients. PREME paves the way to the creation of clinically relevant repositories of faithful patient-derived (C)PDX and 3D models, on which testing precision, NB standard-of-care and experimental medicines.
2024
From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models / Capasso, Mario; Brignole, Chiara; Lasorsa, Vito A.; Bensa, Veronica; Cantalupo, Sueva; Sebastiani, Enrico; Quattrone, Alessandro; Ciampi, Eleonora; Avitabile, Marianna; Sementa, Angela R.; Mazzocco, Katia; Cafferata, Barbara; Gaggero, Gabriele; Vellone, Valerio G.; Cilli, Michele; Calarco, Enzo; Giusto, Elena; Perri, Patrizia; Aveic, Sanja; Fruci, Doriana; Tondo, Annalisa; Luksch, Roberto; Mura, Rossella; Rabusin, Marco; De Leonardis, Francesco; Cellini, Monica; Coccia, Paola; Iolascon, Achille; Corrias, Maria V.; Conte, Massimo; Garaventa, Alberto; Amoroso, Loredana; Ponzoni, Mirco; Pastorino, Fabio. - In: JOURNAL OF TRANSLATIONAL MEDICINE. - ISSN 1479-5876. - 22:1(2024). [10.1186/s12967-024-04954-w]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/959072
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact